Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 199

1.

Financial factors and the implementation of medications for treating opioid use disorders.

Knudsen HK, Roman PM.

J Addict Med. 2012 Dec;6(4):280-6. doi: 10.1097/ADM.0b013e318262a97a.

2.

Medicaid Coverage for Methadone Maintenance and Use of Opioid Agonist Therapy in Specialty Addiction Treatment.

Saloner B, Stoller KB, Barry CL.

Psychiatr Serv. 2016 Jun 1;67(6):676-9. doi: 10.1176/appi.ps.201500228. Epub 2016 Feb 29.

PMID:
26927578
3.

Risk Factors for Relapse and Higher Costs Among Medicaid Members with Opioid Dependence or Abuse: Opioid Agonists, Comorbidities, and Treatment History.

Clark RE, Baxter JD, Aweh G, O'Connell E, Fisher WH, Barton BA.

J Subst Abuse Treat. 2015 Oct;57:75-80. doi: 10.1016/j.jsat.2015.05.001. Epub 2015 May 7.

4.

Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared With Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence.

Jackson H, Mandell K, Johnson K, Chatterjee D, Vanness DJ.

Subst Abus. 2015;36(2):226-31. doi: 10.1080/08897077.2015.1010031. Epub 2015 Mar 16.

5.

A call for evidence-based medical treatment of opioid dependence in the United States and Canada.

Nosyk B, Anglin MD, Brissette S, Kerr T, Marsh DC, Schackman BR, Wood E, Montaner JS.

Health Aff (Millwood). 2013 Aug;32(8):1462-9. doi: 10.1377/hlthaff.2012.0846.

6.

Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions.

Friedmann PD, Hoskinson R, Gordon M, Schwartz R, Kinlock T, Knight K, Flynn PM, Welsh WN, Stein LA, Sacks S, O'Connell DJ, Knudsen HK, Shafer MS, Hall E, Frisman LK; Mat Working Group Of CJ-Dats.

Subst Abus. 2012;33(1):9-18. doi: 10.1080/08897077.2011.611460.

7.

Opioid use disorder during pregnancy in Tennessee: expediency vs. science.

Martin PR, Finlayson AJ.

Am J Drug Alcohol Abuse. 2015;41(5):367-70. doi: 10.3109/00952990.2015.1047502.

PMID:
26186388
8.

Financing and cost of standard and enhanced methadone treatment.

Bradley CJ, French MT, Rachal JV.

J Subst Abuse Treat. 1994 Sep-Oct;11(5):433-42.

PMID:
7869464
9.

Retention in publicly funded methadone maintenance treatment in two Western States.

Deck D, Carlson MJ.

J Behav Health Serv Res. 2005 Jan-Mar;32(1):43-60.

PMID:
15632797
10.

The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine.

Clark RE, Samnaliev M, Baxter JD, Leung GY.

Health Aff (Millwood). 2011 Aug;30(8):1425-33. doi: 10.1377/hlthaff.2010.0532.

PMID:
21821560
11.

Management of opioid-dependent patients: comparison of the cost associated with use of buprenorphine/naloxone or methadone, and their interactions with concomitant treatments for infectious or psychiatric comorbidities.

Roncero C, Domínguez-Hernández R, Díaz T, Fernández JM, Forcada R, Martínez JM, Seijo P, Terán A, Oyagüez I.

Adicciones. 2015 Sep 15;27(3):179-89. English, Spanish.

12.

Medicaid coverage of medications to treat alcohol and opioid dependence.

Mark TL, Lubran R, McCance-Katz EF, Chalk M, Richardson J.

J Subst Abuse Treat. 2015 Aug;55:1-5. doi: 10.1016/j.jsat.2015.04.009. Epub 2015 Apr 16.

PMID:
25921475
13.

Responses of state Medicaid programs to buprenorphine diversion: doing more harm than good?

Clark RE, Baxter JD.

JAMA Intern Med. 2013 Sep 23;173(17):1571-2. doi: 10.1001/jamainternmed.2013.9059. Review. No abstract available.

PMID:
23877740
14.

The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence.

Clark RE, Baxter JD, Barton BA, Aweh G, O'Connell E, Fisher WH.

Health Serv Res. 2014 Dec;49(6):1964-79. doi: 10.1111/1475-6773.12201. Epub 2014 Jul 9.

15.

Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.

Schackman BR, Leff JA, Polsky D, Moore BA, Fiellin DA.

J Gen Intern Med. 2012 Jun;27(6):669-76. doi: 10.1007/s11606-011-1962-8. Epub 2012 Jan 4.

16.

The costs of crime during and after publicly funded treatment for opioid use disorders: a population-level study for the state of California.

Krebs E, Urada D, Evans E, Huang D, Hser YI, Nosyk B.

Addiction. 2017 May;112(5):838-851. doi: 10.1111/add.13729. Epub 2017 Feb 6.

17.

Testing use of payers to facilitate evidence-based practice adoption: protocol for a cluster-randomized trial.

Molfenter T, Kim JS, Quanbeck A, Patel-Porter T, Starr S, McCarty D.

Implement Sci. 2013 May 10;8:50. doi: 10.1186/1748-5908-8-50.

18.

Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio.

Molfenter T, Sherbeck C, Zehner M, Quanbeck A, McCarty D, Kim JS, Starr S.

Subst Abuse Treat Prev Policy. 2015 Mar 28;10:13. doi: 10.1186/s13011-015-0009-2.

19.

Determinants of the availability of hepatitis C testing services in opioid treatment programs: results from a national study.

Frimpong JA, D'Aunno T, Jiang L.

Am J Public Health. 2014 Jun;104(6):e75-82. doi: 10.2105/AJPH.2013.301827. Epub 2014 Apr 17.

20.

Supplemental Content

Support Center